Sandoz receives European Commission approval for Zessly® (infliximab) in gastroenterological, rheumatological and dermatological diseases
(WorldNews Switzerland)

European Commission`s (EC) approval based on comprehensive data package confirming that Zessly® matches safety, efficacy and quality of reference medicine Biosimilars such as Zessly enable earlier patient access to important medicines and positively impact healthcare systems Zessly is the third EC approval for a Sandoz biosimilar in 12 months Holzkirchen, Germany, May 24, 2018 - Sandoz, a Novartis division and the global leader in biosimilars, today announced that the European Commission (EC) has approved Zessly® (infliximab) for use in Europe. Zessly is approved for use in all indications of the reference medicine*** including rheumatoid arthritis, adult Crohn`s disease, pediatric Crohn`s...